Article Text

Download PDFPDF
Anakinra for a refractory case of intermittent hydrarthrosis with a TRAPS-related gene mutation
  1. Mariano Andrés1,
  2. Eliseo Pascual1,2
  1. 1Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain
  2. 2Universidad Miguel Hernández de Elche, Alicante, Spain
  1. Correspondence to Dr Mariano Andrés, Sección de Reumatología, Hospital General Universitario de Alicante, and Universidad Miguel Hernández, Pintor Baeza 12, Alicante 03010, Spain; drmarianoandres{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Intermittent hydrarthrosis (IH) is a rare condition characterised by its periodic schedule: recurrent self-remitting episodes of acute arthritis with a fixed periodicity; this clinical picture has been recognised as a clue for diagnosis for a long time.1 The pathogenesis of IH is unknown. An involvement of mastocytes has been reported.2 Interestingly, Cañete et al 3 found mutations of the Mediterranean fever gene (MEFV) in a small series of patients with IH. For management of the disease, non-steroidal anti-inflammatory drugs, corticosteroids and colchicine are used, generally with good results, but some patients persist with recurrent episodes of arthritis. Here we report our experience with the interleukin-1 (IL-1) inhibitor anakinra in a patient with a …

View Full Text


  • Contributors MA and EP both equally contribute to the writing of this manuscript.

  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.